Suggested remit: To appraise the clinical and cost effectiveness of ruxolitinib within its marketing authorisation for treating moderate atopic dermatitis
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6602
Provisional Schedule
- Expected publication:
- 03 June 2027
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Incyte Biosciences UK (ruxolitinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Allergy UK
- Changing Faces
- Eczema Outreach Support
- Let’s Face it
- Eczema UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- British Association of Dermatologists
- British Dermatological Nursing Group
- British Geriatrics Society
- Primary Care Dermatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Abbvie (upadacitinib)
- Almirall (lebrikizumab)
- Aspen (azathioprine)
- Cipla UK (methotrexate)
- Dexcel pharma (ciclosporin)
- Eli Lilly (baricitinib)
- Esteve pharmaceuticals
- Galderma (nemolizumab)
- Hospira (methotrexate)
- Leo Laboratories (tralokinumab)
- Medac (methotrexate)
- Milpharm (mycophenolate mofetil)
- Morningside Healthcare (methotrexate, mycophenolate mofetil)
- Nordic Pharma (methotrexate)
- Nova Laboratories (azathioprine)
- Novartis Pharmaceuticals (ciclosporin)
- Orion Pharma (methotrexate)
- Pfizer (abrocitinib)
- Roche Products (mycophenolate mofetil)
- Rosemont Pharmaceuticals (methotrexate)
- Sandoz (methotrexate)
- Sanofi (dupilumab)
- Santen UK (ciclosporin)
- Strides Pharma (azathioprine)
- Teva Pharma B.V. (mycophenolate mofetil)
- Tillomed Laboratories (azathioprine,
- Viatris (ciclosporin)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- British Skin Foundation
- Centre of Evidence-based Dermatology, University of Nottingham
- Cochrane Skin Group
- Dermatrust
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 July 2026 | Invitation to participate |
| 21 April 2026 - 20 May 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6602 |
| 21 April 2026 | In progress. Scoping commencing |
| 20 June 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual